Association of German Bronchiectasis Registry Participation With Disease Course

Background Bronchiectasis research has advanced significantly through international and national registries, such as the European bronchiectasis registry (EMBARC) revealing crucial insights into the disease's heterogeneous nature. These efforts underscore the importance of precise patient phenotyping and the identification of underlying causes to improve management and outcomes in bronchiectasis. Study design and methods The prospective, non-interventional PROGNOSIS registry has collected data from over 1500 CT-confirmed adult bronchiectasis patients across 38 German sites, excluding those with cystic fibrosis or lung transplants. Aligned with the EMBARC registry, it ensures comprehensive clinical data collection. Statistical analyses of baseline and follow-up data aim to assess disease progression and patient outcomes. Results Key outcomes include a reduction in the median exacerbations (IQR, 1(1–4) to 1 (1–3), p<0.001) and hospitalizations (IQR, 1(1–2) to 1(1–1), p<0.001) demonstrating an improvement in managing the disease during patients’ participation in the registry. Lung function (ppFEV1, IQR 73%(51–90) to 73%(52–92), p=0.6) remained stable over time, contradicting the expected decline in such chronic lung conditions. There was a significant decrease in active smokers (4.4% to 3.6%, p<0.001), and improvements were seen in sputum quantity and quality. There was an increase in the detection of pathogens, particularly Pseudomonas aeruginosa (32% to 36%, p<0.001). Notable shifts in the underlying causes of bronchiectasis were observed over the registry period, including a decrease in idiopathic cases (35% to 28%, p<0.001) and an increase in cases with a proven etiology. Conclusion The PROGNOSIS registry highlights the critical role of comprehensive management in bronchiectasis, emphasising infection control and treatment adherence. It underscores the need for personalised treatment by identifying the underlying aetiology and reinforces the ongoing importance of research in improving patient care and quality of life.

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2025-12-18
DOI
https://doi.org/10.1183/23120541.01121-2025
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of German Bronchiectasis Registry Participation With Disease Course

Gernot G. U. Rohde, Sivagurunathan Sutharsan, Annegret Zurawski, Nina Adaskina et al.
ERJ Open Research
Cystic Fibrosis Research Advances
article

Association of German Bronchiectasis Registry Participation With Disease Course

Gernot G. U. Rohde, Sivagurunathan Sutharsan, Annegret Zurawski, Nina Adaskina, Felix C. Ringshausen, Isabell Pink, Pontus Mertsch, Sarah Sieber, Grit Barten-Neiner, Jessica Rademacher
article en

Abstract

Background Bronchiectasis research has advanced significantly through international and national registries, such as the European bronchiectasis registry (EMBARC) revealing crucial insights into the disease's heterogeneous nature. These efforts underscore the importance of precise patient phenotyping and the identification of underlying causes to improve management and outcomes in bronchiectasis. Study design and methods The prospective, non-interventional PROGNOSIS registry has collected data from over 1500 CT-confirmed adult bronchiectasis patients across 38 German sites, excluding those with cystic fibrosis or lung transplants. Aligned with the EMBARC registry, it ensures comprehensive clinical data collection. Statistical analyses of baseline and follow-up data aim to assess disease progression and patient outcomes. Results Key outcomes include a reduction in the median exacerbations (IQR, 1(1–4) to 1 (1–3), p<0.001) and hospitalizations (IQR, 1(1–2) to 1(1–1), p<0.001) demonstrating an improvement in managing the disease during patients’ participation in the registry. Lung function (ppFEV1, IQR 73%(51–90) to 73%(52–92), p=0.6) remained stable over time, contradicting the expected decline in such chronic lung conditions. There was a significant decrease in active smokers (4.4% to 3.6%, p<0.001), and improvements were seen in sputum quantity and quality. There was an increase in the detection of pathogens, particularly Pseudomonas aeruginosa (32% to 36%, p<0.001). Notable shifts in the underlying causes of bronchiectasis were observed over the registry period, including a decrease in idiopathic cases (35% to 28%, p<0.001) and an increase in cases with a proven etiology. Conclusion The PROGNOSIS registry highlights the critical role of comprehensive management in bronchiectasis, emphasising infection control and treatment adherence. It underscores the need for personalised treatment by identifying the underlying aetiology and reinforces the ongoing importance of research in improving patient care and quality of life.

ERJ Open Research
Statistisches Bundesamt (DE), Medizinische Hochschule Hannover (DE), Ruhrlandklinik (DE), German Center for Lung Research (DE), Erwin Röver Stiftung (DE), Ludwig-Maximilians-Universität München (DE)
Openalex Percentile: Top 40%
Cystic Fibrosis Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.